Session » Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy V: Imaging and Cardiovascular Outcomes Therapy

Date: Wednesday, November 8, 2017

Time: 11:00AM-12:30PM

Meeting: 2017 ACR/ARHP Annual Meeting

Abstract Number: 2962

MRI Results Following Discontinuation of Methotrexate in Patients with Rheumatoid Arthritis Treated with Subcutaneous Tocilizumab: Results from a Randomized Controlled Trial

Abstract Number: 2963

Sirukumab Improves Synovial Vascularity As Measured By Power Doppler Sonography in Rheumatoid Arthritis Patients from As Early As Week 4 in a Phase 3 Trial

Abstract Number: 2964

Structural Damage in Patients with Very Early RA Is Predicted with Clinical Measures of Baseline Disease Activity: DAS28 (CRP), SDAI, M-DAS28 and RAPID3 but Not CDAI

Abstract Number: 2965

Non-Invasive Imaging Methods for Evaluating the Cardiovascular Involvement in Patients with Rheumatoid Arthritis before and after 18 Months of Treatment with Anti-TNF Drugs

Abstract Number: 2966

Impact of Tofacitinib Treatment Compared with Placebo or Methotrexate on Cardiovascular Risk Scores in Six Phase 3 Randomized Controlled Trials

Abstract Number: 2967

Adding Ultrasound to the Treat-to-Target Strategy Shows No Benefit in Achievement of Remission: Results from the Biodam Cohort

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under embargo once the ACR has notified presenters of their abstract’s acceptance, and cannot be presented at other meetings after this time. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until November 7 at 10:00 AM ET. Journalists with access to embargoed information also cannot release articles before this time.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Permissions and Reprints

For information about abstract permissions and reprints, see ACR Convergence permissions and reprint policies.